Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
BACKGROUND
The luminal subtype of breast cancer is sensitive to anti-estrogen therapy and shows a better prognosis than that of human epidermal growth factor receptor2 (HER2)-enriched or triple-negative breast cancer. However, the luminal type of breast cancer is heterogeneous and can have aggressive clinical features. We investigated the clinical implications of single hormone receptor negativity in a luminal B HER2-negative group.


METHODS
We collected luminal B HER2-negative breast cancer data that were estrogen receptor (ER) and/or progesterone receptor (PR) positive, Ki 67 high (>14 %), and HER2 negative and divided them into the ER- and PR-positive group and the ER- or PR-negative group. We analyzed the clinical and pathological data and survival according to ER or PR loss.


RESULTS
There were no statistical differences in TNM stage, breast and axillary operative methods, or number of tumors between the ER- and PR-positive group and ER- or PR-negative group. However, the ER- or PR-negative group was associated with older age (≥45 years), higher histological grade, lower Bcl-2 expression, and far higher Ki 67 (>50 %). Disease-free survival (DFS) and overall survival (OS) were shorter in the ER- or PR-negative group than that in the ER- and PR-positive group (p = 0.0038, p = 0.0071).


CONCLUSIONS
ER- or PR-negative subgroup showed worse prognosis than ER- and PR-positive subgroup in the luminal B HER2-negative group. We could consider the negativity of ER or PR as prognostic marker in luminal B HER2-negative subtype of breast cancer.
Department of Surgery, Sanggye Paik Hospital, College of Medicine, Inje University, 1342 Dongil-ro, Nowon-gu, Seoul, 139-707, Korea.
Chansub
C
Park
Department of Pathology, Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Korea.
Kyeongmee
K
Park
Department of Diagnostic Radiology, Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Korea.
Jiyoung
J
Kim
Department of Radiologic Oncologist, Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Korea.
Youngjoo
Y
Sin
Department of Surgery, Sanggye Paik Hospital, College of Medicine, Inje University, 1342 Dongil-ro, Nowon-gu, Seoul, 139-707, Korea.
Inseok
I
Park
Department of Surgery, Sanggye Paik Hospital, College of Medicine, Inje University, 1342 Dongil-ro, Nowon-gu, Seoul, 139-707, Korea.
Hyunjin
H
Cho
Department of Surgery, Sanggye Paik Hospital, College of Medicine, Inje University, 1342 Dongil-ro, Nowon-gu, Seoul, 139-707, Korea.
Keunho
K
Yang
Department of Surgery, Sanggye Paik Hospital, College of Medicine, Inje University, 1342 Dongil-ro, Nowon-gu, Seoul, 139-707, Korea.
Byung Noe
BN
Bae
Department of Surgery, Sanggye Paik Hospital, College of Medicine, Inje University, 1342 Dongil-ro, Nowon-gu, Seoul, 139-707, Korea.
Ki Whan
KW
Kim
Department of Surgery, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea.
Sookyung
S
Ahn
Department of Surgery, Sanggye Paik Hospital, College of Medicine, Inje University, 1342 Dongil-ro, Nowon-gu, Seoul, 139-707, Korea. gsrad@hanmail.net.
Geumhee
G
Gwak
D000367:Age Factors; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology; D002277:Carcinoma / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012189:Retrospective Studies; D021701:Sentinel Lymph Node Biopsy
D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human
Breast cancer; Estrogen receptor; Luminal B; Progesterone receptor; Prognosis